|
Martin McGlynn joined the company on January 15, 2001. Mr. McGlynn's experience includes several decades of international experience in the Life Sciences industry. Prior to joining StemCells, Inc., he was President and CEO of Pharmadigm, Inc., a privately held company in Salt Lake City, Utah, which is engaged in research and development in the fields of inflammation and genetic immunization. During his time at Pharmadigm, Mr. McGlynn took the company through four rounds of financing, raising in excess of $50 million in private and venture capital. Mr. McGlynn previously held positions as President of Anaquest Inc., the Pharmaceutical Products Division of BOC Health Care; Vice President, Abbott International; and President and General Manger of Abbot Canada Ltd. He holds a Bachelor of Commerce degree from University College, Dublin, and diplomas in Industrial engineering and Production Planning from the Irish Institute of Industrial Engineering and the University of Birmingham, England, respectively.
| 